Stay updated with breaking news from Codexis Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Codexis (NASDAQ:CDXS – Get Free Report) was downgraded by stock analysts at TD Cowen from an “outperform” rating to a “market perform” rating in a report issued on Monday, Marketbeat reports. They currently have a $4.00 price objective on the biotechnology company’s stock, down from their prior price objective of $21.00. TD Cowen’s price objective […]
BlackRock Inc. (Trades, Portfolio), a leading global investment management corporation, has recently increased its stake in Codexis Inc., a prominent player in the biotechnology industry. This article provides an in-depth analysis of the transaction, profiles of both BlackRock Inc. (Trades, Portfolio) and Codexis Inc., and an examination of Codexis Inc.'s financial health and stock performance.
Codexis (NASDAQ:CDXS – Get Free Report) and LanzaTech Global (NASDAQ:LNZA – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends. Insider & Institutional Ownership 88.0% of Codexis shares […]
Codexis (NASDAQ:CDXS – Get Free Report) issued its quarterly earnings results on Thursday. The biotechnology company reported ($0.17) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.04, Briefing.com reports. Codexis had a negative net margin of 41.17% and a negative return on equity of 32.75%. The company had revenue of […]
Codexis (NASDAQ:CDXS – Get Free Report) issued its quarterly earnings results on Thursday. The biotechnology company reported ($0.17) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.04, Briefing.com reports. Codexis had a negative net margin of 41.17% and a negative return on equity of 32.75%. The company had revenue of […]